Almac Group, a global contract development and manufacturing organization, is investing $65 million in a 100,000 ft2 expansion of clinical supply operations at its North American headquarters in Souderton, PA. The capital investment plan increases clinical capacity at the facility by 60%, with additional cold and ultra-low storage and just-in-time processing capabilities which is forecasted to support the industry trend towards biologics and advanced therapeutic medicinal products (ATMPs). 
 
Almac’s expansion will break ground in early 2023 and upon completion, will bring the company’s North American headquarters footprint to a total of 340,000 ft2. Capacity will increase specifically in the following areas:
 

• 200% increase in 2-8°C Storage: 
• 140% increase in 2-8°C Packaging
• 100% increase in 20°C Packaging
• 30% increase in 15-25°C Storage
• 115% increase in Ultra-Low Storage
• 100% increase in Just-In-Time Manufacturing

 
Robert Dunlop, President and Managing Director, Almac Clinical Services, said, “Drug development and clinical trials continue to evolve across the world, with sponsors expanding their pipelines to focus on biologics, vaccines and advanced therapy medicinal products. Almac is at the forefront of building supply chain expertise and capacity for this evolution. We are committed to investing in our clients’ future challenges and are delighted that this expansion provides us with a stronger ability to service our growing customer base.”
 
The North American Headquarters expansion follows the company’s July announcement that the overall planned investment in Pennsylvania operations and facilities will total $93.5 million over the next three years and will total over $250 million for the Group globally during the same period. 
 
The company plans to add 355 new Montgomery County-based jobs to support the forecasted growth and is actively recruiting for positions across disciplines and experience levels.